News | September 05, 2013

ITC Nexus Acquires Accumetrics

September 5, 2013 — ITC Nexus Holding Co., a company in hemostasis management and point-of-care (POC) testing, announced it has acquired Accumetrics, a specialist in assessing patient response to all major antiplatelet therapies. Terms of the transaction were not disclosed.

ITC develops, manufactures and markets the Hemochron product line, a market-leading POC system used to measure clotting activity for patients undergoing anticoagulation therapy. Accumetrics develops, manufactures and markets the VerifyNow product line, a market-leading POC system used to measure platelet reactivity following antiplatelet therapies, including ADP receptor antagonists and aspirin.

"ITC has a history of innovation and leadership in point-of-care coagulation testing, and Accumetrics is a pioneer and leader in point-of-care platelet function testing," said John Sperzel, CEO of ITC. "The combination of ITC's Hemochron and Accumetrics' VerifyNow product lines creates a leading hospital-based POC cardiovascular diagnostics business."

"Accumetrics has played a leading role in the development of the antiplatelet monitoring market. The performance of the VerifyNow system has been demonstrated in numerous clinical studies," said Accumetrics CEO Timothy I. Still. "I am confident that combining Accumetrics with ITC provides the best opportunity to accelerate the global adoption of the VerifyNow system."

Sperzel will serve as CEO of the combined company and Greg Tibbitts, CFO of Accumetrics, will serve as CFO of the combined company. Now that the transaction has closed, the process of integrating the ITC and Accumetrics businesses will begin immediately and the leadership teams will work closely to ensure a seamless transition for customers.

The combined company will assume a new name, Accriva Diagnostics, and its corporate headquarters will be established in San Diego.

For more information: www.itcmed.com, www.accumetrics.com


Related Content

News | Pharmaceuticals

November 28, 2022 – Tenaya Therapeutics, a clinical-stage biotechnology company with a mission to discover, develop and ...

Home November 28, 2022
Home
News | Pharmaceuticals

October 17, 2022 — Global Health has paid a deadly price for not using simple, low-cost blood pressure lowering drugs ...

Home October 17, 2022
Home
News | Pharmaceuticals

September 6, 2022 — An analysis of more than 12,000 patients has found that the SGLT2 inhibitors dapagliflozin and ...

Home September 06, 2022
Home
News | Pharmaceuticals

September 6, 2022 — Stopping statin treatment early could substantially reduce lifetime protection against heart disease ...

Home September 06, 2022
Home
News | Pharmaceuticals

July 25, 2022 DalCor Pharmaceuticals announced the results of the dal-GenE Phase 3 cardiovascular precision medicine ...

Home July 25, 2022
Home
News | Pharmaceuticals

May 24, 2022 — Amarin Corporation plc announced that research on the potential population health impact and cost ...

Home May 24, 2022
Home
News | Pharmaceuticals

May 24, 2022 — The U.S. Food and Drug Administration (FDA) has issued a statement that Teva Pharmaceuticals USA has ...

Home May 24, 2022
Home
News | Pharmaceuticals

May 17, 2022 — Amarin Corporation plc announced that research on the potential population health impact and cost ...

Home May 17, 2022
Home
News | Pharmaceuticals

May 13, 2022 — Bristol Myers Squibb’s mavacamten will stand rather unchallenged in the hypertrophic cardiomyopathy (HCM) ...

Home May 13, 2022
Home
News | Pharmaceuticals

April 29, 2022 — Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved Camzyos ...

Home April 29, 2022
Home
Subscribe Now